The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | SAR408701 vs docetaxel in metastatic non-squamous NSCLC
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the phase III CARMEN-LC03 trial (NCT04154956) comparing SAR408701, an antibody-drug conjugate (ADC), with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) failing chemotherapy and immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
